Abstract
Chimeric antigen receptor (CAR) T cells targeting CD19 have changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma. Infections are one of the most freque... Plain language summary Lymphoma is an aggressive blood cell cancer. A treatment called chimeric antigen receptor (CAR) T-cell therapy has recently been developed for patients with lymphoma and othe...
Funding Information
  • Regeneron, Bristol Myers Squibb, Takeda and Novartis

This publication has 20 references indexed in Scilit: